Drug Database
Back to search

Canada· CA-DIN-02353903

FEIBA NF

A faktor viii-inhibitor bypass aktivität - feiba product containing anti-inhibitor coagulant complex, registered in Canada by TAKEDA CANADA INC. The same ATC class is registered in 10 of our 19 countries.

ATC B02BD03

Checked against Health Canada Drug Product Database (Canada) on

Informational only — not a medical device.

SOURCE REGISTER · CAHealth Canada Drug Product Database (Ca…normalisedFEIBA NFATCB02BD03REGISTER NO.CA-DIN-02353903PACKS LISTED0CHECKEDOctober 1, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about anti-inhibitor coagulant complexAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Faktor viii-inhibitor bypass aktivität - feiba is registered in 10 of 19 countries.

Countries holding a registration under ATC B02BD03 (faktor viii-inhibitor bypass aktivität - feiba), each read from that country’s own register.

  • This record: Canada, from Health Canada Drug Product Database (Canada)
  • 6 of them publish a price we can compare per daily dose
Search faktor viii-inhibitor bypass aktivität - feiba products by name

Faktor viii-inhibitor bypass aktivität - feiba · ATC B02BD03

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Health Canada Drug Product Database (Canada)
Active substance
ANTI-INHIBITOR COAGULANT COMPLEX
Manufacturer
TAKEDA CANADA INC
Country
Canada (CA)
ATC code
B02BD03
ATC class
Faktor VIII-Inhibitor Bypass Aktivität - FEIBA
Defined daily dose
7 TSD, E
Reimbursed
Not published by this register
Source register
Health Canada Drug Product Database (Canada)
Last checked
October 1, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

5 interactions on record for faktor viii-inhibitor bypass aktivität - feiba.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check faktor viii-inhibitor bypass aktivität - feiba against other medicinesHow interaction checks work

Faktor viii-inhibitor bypass aktivität - feiba · interactions on record

5 records

  • 4 severe
  • 1 moderate

Most severe, free to view

  • Aminocaproic acidB02AA01severe
  • Tranexamic acidB02AA02severe
  • AprotininB02AB01severe
  • EmicizumabB02BX06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Faktor viii-inhibitor bypass aktivität - feiba in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All faktor viii-inhibitor bypass aktivität - feiba products

Authorised across Europe · EMA

The same active substance is authorised in 28 EEA countries. Names it is sold under:

  • Austria · Feiba
  • Belgium · Feiba
  • Bulgaria · Фейба
  • Cyprus · Feiba
  • Czechia · Feiba
  • Germany · Feiba
  • Denmark · Feiba
  • Estonia · Feiba
  • Spain · Feiba
  • Finland · Feiba
  • France · Feiba
  • United Kingdom (Northern Ireland) · Feiba
  • Greece · Feiba
  • Croatia · Feiba
  • Hungary · Feiba Nf
  • Ireland · Feiba
  • Italy · Feiba
  • Lithuania · Feiba
  • Latvia · Feiba
  • Malta · Feiba
  • Netherlands · Feiba
  • Norway · Feiba
  • Poland · Feiba Nf
  • Portugal · Feiba Nf
  • Romania · Feiba
  • Sweden · Feiba
  • Slovenia · Feiba
  • Slovakia · Feiba

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8e0d7822-0a4b-4da0-9ae4-271cd8161b96
GET /v1/drugs/8e0d7822-0a4b-4da0-9ae4-271cd8161b96?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "din": "02353903",
  "form": "KIT",
  "class": "Human",
  "routes": [
    "INTRAVENOUS"
  ],
  "source": "health_canada_dpd",
  "status": "MARKETED",
  "atc_raw": "B02BD03",
  "schedule": [
    "Schedule D"
  ],
  "drug_code": "83912",
  "strengths": [
    "3250 UNIT"
  ],
  "ahfs_class": null,
  "substances": [
    "ANTI-INHIBITOR COAGULANT COMPLEX"
  ],
  "product_categorization": null
}
API referenceMCP serverPlans

See everything about faktor viii-inhibitor bypass aktivität - feiba.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console